Indegene Ltd. stands out in the Pharmaceuticals & Drugs sector with impressive revenue growth and profitability metrics compared to its peers. Despite a high PE ratio, its strong ROE and significant revenue growth signal healthy operational performance, making it a potential growth stock. However, caution is advised due to a relatively high PEG ratio, suggesting that growth may be priced in.

• • Indegene Ltd. shows a robust revenue growth of 9.64% YoY and a notable 38.9% over three years.
• • High ROE of 27.56%, indicating effective management and profitability.
• • Despite a high PE ratio of 72.37, the growth prospects remain attractive.